Drugs that contain Everolimus
1. List of Afinitor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(11 months ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(11 months ago) | |
|
US8778962
(Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(5 months ago) | |
|
US8436010
(Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(5 months ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) | |
|
US8410131
(Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(3 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic
Dosage: TABLET;ORAL
2. List of Afinitor Disperz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(11 months ago) | |
|
US8778962
(Pediatric) | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(5 months ago) | |
| US8617598 | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep, 2022
(4 months ago) | |
|
US8617598
(Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(a month from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 10, 2025 |
Market Authorisation Date: 29 August, 2012
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive treatment of patients with tsc-associated partial-onset seizures
Dosage: TABLET, FOR SUSPENSION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic